CoChat

The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.

The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

Yong, Hae-Young, Koh, Min-Soo, Moon, Aree · 2009 · Expert Opinion on Investigational Drugs

Abstract

BACKGROUND: The p38 mitogen-activated protein kinase (MAPK) is activated by various pro-inflammatory and stressful stimuli. Mounting evidence suggests that the p38 MAPK signaling cascade is involved in various biological responses other than inflammation such as cell proliferation, differentiation, apoptosis and invasion, suggesting that the p38 MAPK can serve as a potential therapeutic target for the treatment of not only inflammatory diseases but also cancer. METHODS: The unique characteristics of p38 MAPK are summarized with regard to activation and function of p38 MAPK signaling cascades. We then discuss the involvement of p38 MAPK in diseases and the implications of the possible therapeutic use of p38 MAPK inhibitors. The p38 MAPK inhibitors that have been used in the in vitro/in vivo systems as well as in the clinical trials are summarized. RESULTS/CONCLUSION: The p38 MAPK plays an important role in key cellular processes related to inflammation and cancer. Understanding the signal transduction mechanisms and gene regulation by p38 MAPK provides useful information in the development of p38 MAPK inhibitors with therapeutic benefits with reduced side effects. In this review, we summarize and present the list of p38 MAPK inhibitors in in vitro/in vivo studies as well as in clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1517/13543780903321490

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 141 references

Research works printed but not linked: 15

  1. Kim MS, 2003, Cancer Res, 63, 5454
  2. 10.1111/j.1572-0241.2003.07660.x · doi:10.1111/j.1572-0241.2003.07660.x · Paper page
  3. Lim SJ, 2006, Oncol Rep, 16, 1131
  4. Han YC, 2007, Ai Zheng, 26, 48
  5. Simon C, 1998, Cancer Res, 58, 1135
  6. She QB, 2001, Cancer Res, 61, 1604
  7. Karahashi H, 2000, Biochem Biophys Acta, 1502, 207
  8. Kim ES, 2004, Int J Oncol, 25, 1375
  9. Dominguez C, 2005, Curr Opin Drug Discov Devel, 8, 421
  10. Mongin-Bulewski C, 2002, Drug Discovery Technology 2002 (Part V) - Overnight Report
  11. Alten RE, 2009, Ann Rheum Dis
  12. Behr TM, 2003, Curr Opin Investig Drugs, 4, 1059
  13. Braddock M, 2003, Inflammation in drug discovery and development SRI's seventh international meeting
  14. Pargellis C, 2003, Curr Opin Investig Drugs, 4, 566
  15. Fitzgerald CE, 2003, MAP kinase quinazoline and pyridol-pyrimidine inhibitor specificity Nat Struct Biol, 10, 764

Cited by

See all 458

Metadata

Authors
Yong, H.-Y., Koh, M.-S., & Moon, A.
Affiliations
Duksung Women's University (KR)
Venue
Expert Opinion on Investigational Drugs
Published
2009-10-23
Volume
18
Issue
12
Pages
1893-1905
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2049204919
Cited by
422
References
141
Citations by year
2026: 20 · 2025: 50 · 2024: 77 · 2023: 46 · 2022: 52 · 2021: 27 · 2020: 22 · 2019: 13 · 2018: 10 · 2017: 10 · 2016: 11 · 2015: 17 · 2014: 14 · 2013: 21 · 2012: 15
FWCI
0.82
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Korea Science and Engineering Foundation
  • Johnson and Johnson
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
p38 MAPK, MAPK inhibitors, inflammatory diseases, cancer, MAPK signaling, signal transduction, gene expression regulation, apoptosis, cell proliferation, clinical trials, drug development
MeSH terms
Clinical Trials as Topic, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Inflammation, Neoplasms, Signal Transduction, Drugs, Investigational, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. https://app.cochat.ai/papers/10.1517/13543780903321490
The paper
Yong, H.-Y., Koh, M.-S., & Moon, A. (2009). The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780903321490

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.